Evolus Inc (EOLS) - Net Assets
Based on the latest financial reports, Evolus Inc (EOLS) has net assets worth $-28.78 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($220.65 Million) and total liabilities ($249.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Evolus Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-28.78 Million |
| % of Total Assets | -13.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | -128.22% |
| 10-Year Change | N/A |
| Growth Volatility | 161.14 |
Evolus Inc - Net Assets Trend (2015–2025)
This chart illustrates how Evolus Inc's net assets have evolved over time, based on quarterly financial data. See Evolus Inc (EOLS) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Evolus Inc (2015–2025)
The table below shows the annual net assets of Evolus Inc from 2015 to 2025. For live valuation and market cap data, see Evolus Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-23.11 Million | -518.44% |
| 2024-12-31 | $5.52 Million | +126.69% |
| 2023-12-31 | $-20.69 Million | -211.84% |
| 2022-12-31 | $18.50 Million | -77.41% |
| 2021-12-31 | $81.88 Million | +212.22% |
| 2020-12-31 | $-72.96 Million | -191.82% |
| 2019-12-31 | $79.46 Million | -5.84% |
| 2018-12-31 | $84.38 Million | +211.70% |
| 2017-12-31 | $-75.54 Million | -963.09% |
| 2016-12-31 | $-7.11 Million | -159.21% |
| 2015-12-31 | $12.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evolus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 61429900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-156.00K | % |
| Other Components | $638.09 Million | % |
| Total Equity | $-23.11 Million | 100.00% |
Evolus Inc Competitors by Market Cap
The table below lists competitors of Evolus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangxi Fenglin Wood Industry Group Co Ltd
SHG:601996
|
$441.23 Million |
|
Anji Foodstuff Co Ltd
SHG:603696
|
$441.23 Million |
|
ARTS Group Co Ltd
SHG:603017
|
$441.34 Million |
|
Tivan Ltd
AU:TVN
|
$441.47 Million |
|
Shenyang Brilliant Elevator Group Co Ltd
SHE:002689
|
$441.21 Million |
|
Rieter Holding AG
SW:RIEN
|
$441.20 Million |
|
Shanghai Tianchen Co Ltd
SHG:600620
|
$441.12 Million |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
$441.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evolus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,522,000 to -23,106,000, a change of -28,628,000 (-518.4%).
- Net loss of 51,641,000 reduced equity.
- Other comprehensive income increased equity by 749,000.
- Other factors increased equity by 22,264,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.64 Million | -223.5% |
| Other Comprehensive Income | $749.00K | +3.24% |
| Other Changes | $22.26 Million | +96.36% |
| Total Change | $- | -518.44% |
Book Value vs Market Value Analysis
This analysis compares Evolus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.65 | $6.75 | x |
| 2016-12-31 | $-0.38 | $6.75 | x |
| 2017-12-31 | $-3.20 | $6.75 | x |
| 2018-12-31 | $3.46 | $6.75 | x |
| 2019-12-31 | $2.81 | $6.75 | x |
| 2020-12-31 | $-2.16 | $6.75 | x |
| 2021-12-31 | $1.64 | $6.75 | x |
| 2022-12-31 | $0.33 | $6.75 | x |
| 2023-12-31 | $-0.36 | $6.75 | x |
| 2024-12-31 | $0.09 | $6.75 | x |
| 2025-12-31 | $-0.36 | $6.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evolus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.38%
- • Asset Turnover: 1.32x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-163.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -259.22% | 0.00% | 0.00x | 6.77x | $-32.31 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.35 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $3.07 Million |
| 2018 | -55.54% | 0.00% | 0.00x | 2.04x | $-55.31 Million |
| 2019 | -113.31% | -257.79% | 0.15x | 3.03x | $-97.98 Million |
| 2020 | 0.00% | -288.31% | 0.27x | 0.00x | $-155.72 Million |
| 2021 | -57.17% | -46.96% | 0.39x | 3.14x | $-55.00 Million |
| 2022 | -402.25% | -50.07% | 0.84x | 9.62x | $-76.26 Million |
| 2023 | 0.00% | -30.52% | 1.07x | 0.00x | $-59.62 Million |
| 2024 | -913.07% | -18.94% | 1.14x | 42.12x | $-50.97 Million |
| 2025 | 0.00% | -17.38% | 1.32x | 0.00x | $-49.33 Million |
Industry Comparison
This section compares Evolus Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $672,825,525
- Average return on equity (ROE) among peers: -42.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evolus Inc (EOLS) | $-28.78 Million | -259.22% | N/A | $441.23 Million |
| Aurora Cannabis Inc (ACB) | $4.40 Billion | -6.66% | 0.28x | $174.42 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $119.33 Million | -64.45% | 2.05x | $251.46 Million |
| Alkermes Plc (ALKS) | $1.20 Billion | -13.13% | 0.49x | $7.39 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $5.18 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $272.40 Million | -8.80% | 0.34x | $194.40 Million |
| ANI Pharmaceuticals Inc (ANIP) | $19.15 Million | -241.27% | 1.34x | $1.80 Billion |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more